BioSpace News Archive

Business

SimBioSys and Mayo Clinic Enter Strategic Collaboration to Advance AI-powered Digital Precision Medicine Platform for Cancer Patients

SimBioSys announced today it has entered into a strategic collaboration agreement with Mayo Clinic for the development of novel digital precision medicine solutions for breast cancer patients.

January 2, 2024
·
3 min read
Biotech Bay

Scribe Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Scribe Therapeutics Inc. today announced that Benjamin Oakes, Ph.D., Chief Executive Officer of Scribe, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT in San Francisco, CA.

January 2, 2024
·
1 min read
Deals

Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announces it has completed its previously announced acquisition of assets related to Odyssey Health, Inc.’s (OTCQB: ODYY) (“Odyssey”) proprietary neurological drug therapies and technologies.

January 2, 2024
·
8 min read
Business

Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications

Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation (A063160.KS) for CKDB-501, a neuromodulator BoNT/A protein.

January 2, 2024
·
2 min read
Drug Development

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Spero Therapeutics, Inc. announced the first patient, first visit for PIVOT-PO, a global pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infections, including acute pyelonephritis.

January 2, 2024
·
7 min read
Genetown

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

Prime Medicine, Inc. (Nasdaq: PRME) today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 2:15 p.m. PT (5:15 p.m. ET) in San Francisco, CA.

January 2, 2024
·
1 min read
BioCapital

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

Gain Therapeutics, Inc. announced that a late-breaking abstract with new data of GT-02287 in preclinical models of Parkinson’s disease has been accepted for a platform presentation at the 20th Annual WORLDSymposium™ being held February 4-9, 2024 in San Diego, CA.

January 2, 2024
·
4 min read
Biotech Bay

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics, Inc. (Nasdaq: RAPT) today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:00 a.m. Pacific Time.

January 2, 2024
·
1 min read
Job Trends

AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024.

January 2, 2024
·
1 min read
BioMidwest

SomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting “FOR” Pending Merger with Standard BioTools

SomaLogic, Inc., a leader in proteomics technology, sent the following open letter to stockholders urging them to vote “FOR” the value maximizing transaction with Standard BioTools.

January 2, 2024
·
15 min read